Sugi Predict

Sugi Predict / Compounds / SCHEMBL1955385

SCHEMBL1955385

SCHEMBL1955385

C1CC(NC2CC2)CCN1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 2/20 0.48
▸ GNAI3 P08754 3/20 0.42
▸ GNAO1 P09471 3/20 0.42
▸ GNAI1 P63096 3/20 0.42
▸ POLB P06746 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ KDM1A O60341 11/20 0.42
▸ MAOB P27338 4/20 0.42
▸ CISD1 Q9NZ45 1/20 0.42
▸ SLC6A2 P23975 1/20 0.42
▸ HTR1B P28222 1/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ KCNH2 Q12809 1/20 0.39
▸ MAOA P21397 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29035917 0.97 EPHX1 (0.46) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL3237330 0.97 EPHX1 (0.50) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL23900748 0.89 ALDH1A1 (0.48) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL13902993 0.88 ALDH1A1 (0.53) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL3818790 0.88 ALDH1A1 (0.61) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL23547389 0.85 ALDH1A1 (0.67) EPHX1GNAI3GNAO1GNAI1POLB
Hydrochloric Acid SCHEMBL542931 0.85 ALDH1A1 (0.58) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL24312790 0.85 KCNH2 (0.44) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL2280475 0.85 ALDH1A1 (0.67) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL23547305 0.85 ALDH1A1 (0.67) EPHX1GNAI3GNAO1GNAI1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024064026-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-03-28 — — WO disclosed
US-11806346-B2 HTT modulators for treating Huntington's disease CHDI FOUNDATION, INC. (US) 2023-11-07 — — US disclosed
WO-2023034811-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 — — WO disclosed
US-20220409615-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI FOUNDATION, INC. 2022-12-29 — — US disclosed
US-11382872-B2 LSD1 inhibitors as skeletal muscle hypertrophy inducers CYTOO (FR) 2022-07-12 — — US disclosed
WO-2022053520-A1 LSD1 INHIBITORS FOR USE IN THE TREATMENT AND PREVENTION OF FIBROSIS OF TISSUES UNIVERSITÉ D'AIX MARSEILLE (FR) 2022-03-17 — — WO disclosed
WO-2021195723-A1 \"METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS\ THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2021-10-07 — — WO disclosed
EP-3736265-A1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS Oryzon Genomics, S.A. (ES) 2020-11-11 — — EP disclosed
EP-2768805-B1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS ORYZON GENOMICS SA (ES) 2020-03-25 — — EP disclosed
US-20200054578-A1 LSD1 INHIBITORS AS SKELETAL MUSCLE HYPERTROPHY INDUCERS CYTOO (FR) 2020-02-20 — — US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 — — US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 — — EP disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 — — US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 — — US disclosed
EP-1305048-A2 INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES Wockhardt Limited (IN) 2003-05-02 — — EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 — — US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 — — WO disclosed
US-20020177559-A1 Quinolone derivatives WOCKHARDT LIMITED 2002-11-28 — — US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 — — WO disclosed
WO-2002009758-A2 INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES WOCKHARDT LIMITED (IN) 2002-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 EPHX1 3090/4885GNAI3 331/4885GNAO1 1758/4885
US-11382872-B2 LSD1 inhibitors as skeletal muscle hypertrophy inducers KDM1B, CPT1B, KDM1A EPHX1 3262/4885GNAI3 2506/4885GNAO1 2993/4885
US-20220409615-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 EPHX1 4091/4885GNAI3 579/4885GNAO1 957/4885
US-20200054578-A1 LSD1 INHIBITORS AS SKELETAL MUSCLE HYPERTROPHY INDUCERS KDM1B, KDM1A, CPT1B EPHX1 3220/4885GNAI3 2194/4885GNAO1 2793/4885
US-11806346-B2 HTT modulators for treating Huntington's disease HTT, HYPK, ATXN2 EPHX1 4091/4885GNAI3 579/4885GNAO1 957/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 EPHX1 2228/4885GNAI3 963/4885GNAO1 3210/4885
US-20020177559-A1 Quinolone derivatives ABCB11, ABCB1, ABCG2 EPHX1 834/4885GNAI3 1128/4885GNAO1 1437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.